FAQ

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 

Topic mentions per year

Topic mentions per year

1999-2016
02419992016

Related topics

Related topics

2 relations

Broader (1)

Serine

Narrower (1)

ombrabulin

Related mentions per year

Related mentions per year

1943-2018
19401960198020002020
AC 7700
Serine
ombrabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.
OBJECTIVES To evaluate the early tumor vasculature disrupting effects of the AVE8062 molecule and the feasibility of dynamic… (More)
Is this relevant?
2007
2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… (More)
Is this relevant?
2003
2003
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.
The in vivo combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin (CDDP) was examined. The… (More)
Is this relevant?
2003
2003
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
We previously reported that a novel combretastatin A-4 derivative, AC7700, has remarkable antitumour effects because of an… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2003
2003
Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of…
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… (More)
Is this relevant?
2002
2002
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
Background. Unlike the many chemotherapeutic agents that do not effectively stop blood flow or induce necrosis in hepatocellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2001
2001
Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
BACKGROUND Using several transplanted tumors in rats and mice, we have recently shown that the acute extensive necrosis of tumor… (More)
Is this relevant?
1999
1999
A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.
AC-7700, a novel combretastatin A-4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… (More)
Is this relevant?
1999
1999
Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
The relation between tumor tissue blood flow (tBF) reduction and antitumor effects was investigated. Changes in tBF of normal… (More)
Is this relevant?